Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ST-002
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sterotherapeutics Announces Initiation of a Phase 2 for Cushing's Syndrome
Details : ST-002 is a glucocorticoid receptor antagonist, small molecule drug candidate which is currently being evaluated for the treatment of cushing's syndrome.
Product Name : ST-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : ST-002
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma
Details : The licensed compounds are highly selective matrix metalloproteinase 13 (MMP-13) inhibitors that display robust modulation of osteoclastogenesis with excellent solubility and stability that portend to be highly effective add-on treatments to the current ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Fluasterone
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : SteroTherapeutics will provide the study drug (non-androgenic analogue of dehydroepiandrosterone) and placebo to enable the NICHD to conduct the Phase 2 clinical trial in the treatment of the manifestations of Cushing syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
February 12, 2020
Lead Product(s) : Fluasterone
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement